Mayo Clinic Pharmacy Grand Rounds

Celebrating diversity: challenges and strategies to promote pharmacogenomics translation across populations

Serena Mitaly, PharmD shares strategies for pharmacogenomic research translation to reduce health disparities.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

What’s the Best for CRS?

Devon Stonerock, PharmD, Uzo Abajue, PharmD and Divya Khandekar, PharmD describe cytokine release syndrome (CRS), the literature surrounding CRS and options for CRS management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Pitter Patter, Let’s Get ATTR: Medications for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Kelli Herrin, PharmD reviews the pathophysiology of transthyretin amyloidosis cardiomyopathy and provides updates on medication options.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Updates on the Clozapine REMS Program: An Important Relic or Fool’s Gold of Safety?

Jonathan Leung, PharmD, BCPS, BCPP provides updates on the clozapine REMS program, reviews the therapeutic benefits of clozapine, as well as key adverse events.  

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

On Another Level: The Role of Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Sarah A. Chase, PharmD reviews the pathophysiology and current treatment strategies for inflammatory bowel disease, defines the clinical application of therapeutic drug monitoring of biologic therapies used in inflammatory bowel disease and discusses biologic therapy optimization based on therapeutic drug monitoring.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

All-In on Insulin? Use of High-Dose Insulin Euglycemic Therapy in Calcium Channel Blocker Overdose

Kyle A. Hess, PharmD, BCPS Twitter: @KyleHessPharmD describes the pathophysiology of calcium channel blocker overdose, explains the rationale for use of insulin-euglycemic therapy in calcium channel blocker overdose and identifies differences between the pathophysiology of dihydropyridine overdose and non-dihydropyridine overdose.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Measuring Value in Drug Therapy

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA (Twitter: @sasoefje) describes the relationship between value and quality, defines quality and how quality measures will impact healthcare in the coming years, and demonstrates how organizations may use quality measures to improve value.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Verification Decision Support: May AI Take Your Order?

Benjamin J. Anderson, PharmD, MPH, FASHP and Diana J. Schreier, PharmD, MBA, BCPS recognize the history and regulations for prospective medication order review, describe the technical landscape for verification decision support and explore real-world verification decision support outcomes.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

A Hard-Pressed Debate: The Role of Terlipressin in Hepatorenal Syndrome

Nikitha Yagnala, PharmD and Andy J. Jatis, PharmD, BCPS describe the pathophysiology of hepatorenal syndrome (HRS), describe the pathophysiology of hepatorenal syndrome (HRS) and outline an optimal patient care plan for the management of HRS.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

 

Freezing Ethylene Glycol Toxicity

Kamryn R. Storm, PharmD (Twitter @KRStorm) outlines the mechanism of toxicity for ethylene glycol, identifies clinical findings of ethylene glycol toxicity and selects treatment regimens for suspected ethylene glycol toxicity.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.